Brachytherapy
Volume 5, Issue 3 , Pages 157-164 , July 2006

Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer

Received 29 November 2005 ,Revised 16 March 2006 ,Accepted 17 March 2006.

References 

  1. Galalae RM, Martinez A, Mate T, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:1048–1055
  2. Morton GC. The emerging role of high-dose-rate brachytherapy for prostate cancer. Clin Oncol (R Coll Radiol). 2005;17:219–227
  3. Martin T, Roddiger S, Kurek R, et al. 3D conformal HDR brachytherapy and external beam irradiation combined with temporary androgen deprivation in the treatment of localized prostate cancer. Radiother Oncol. 2004;71:35–41
  4. Martinez A, Galalae R, Gonzalez J, et al. Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol. 2003;169:974–979discussion 979–80
  5. Demanes DJ, Rodriguez RR, Schour L, et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys. 2005;61:1306–1316
  6. Deger S, Boehmer D, Reigas J, et al. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer. Eur Urol. 2005;47:441–448
  7. D'Amico AV, Whittington R, Malkowicz SB, et al. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage. Int J Radiat Oncol Biol Phys. 1999;45:1227–1233
  8. D'Amico AV, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  9. Wambersie A, Landberg T. ICRU Report 62: prescribing, recording and reporting photon beam therapy (Supplement to ICRU Report 50) 1999.
  10. American Society for Therapeutic Radiology and Oncology Consensus Panel . Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035
  11. Pickles T, Kim-Sing C, Morris WJ, et al. Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys. 2003;57:11–18
  12. Hsu IC, Pickett B, Shinohara K, et al. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: Potential for dose escalation. Int J Radiat Oncol Biol Phys. 2000;46:851–858
  13. Chappell R, Fowler J, Ritter M. New data on the value of alpha/beta–Evidence mounts that it is low. Int J Radiat Oncol Biol Phys. 2004;60:1002–1003
  14. Fowler JF, Mitter MA, Fenwich JD, et al. How low is the alpha/beta ratio for prostate cancer? In regard to Wang et al., IJROBP 2003;55:194-203. Int J Radiat Oncol Biol Phys. 2003;57:593–595author reply 595–6
  15. Brenner DJ, Martinez AA, Edmundson GK. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6–13
  16. Wang JZ, Li XA, Yu CX, et al. The low alpha/beta ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell us?. Int J Radiat Oncol Biol Phys. 2003;57:1101–1108
  17. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  18. Pellizzon AC, et al. Late urinary morbidity with high dose prostate brachytherapy as a boost to conventional external beam radiation therapy for local and locally advanced prostate cancer. J Urol. 2004;171:1105–1108
  19. Martinez AA, Pataki J, Edmundson G, et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. Int J Radiat Oncol Biol Phys. 2001;49:61–69
  20. Grills IS, Martinez AA, Hollander M, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol. 2004;171:1098–1104
  21. Yoshioka Y, Nose T, Yoshida K, et al. High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: Treatment description and preliminary results of a phase I/II clinical trial. Int J Radiat Oncol Biol Phys. 2000;48:675–681

PII: S1538-4721(06)00042-0

doi: 10.1016/j.brachy.2006.03.004

Brachytherapy
Volume 5, Issue 3 , Pages 157-164 , July 2006

Article Tools

* Image Usage & Resolution